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ABSTRACT
Dendritic cells (DCs) are key effectors in innate immunity and play critical roles in triggering adaptive immune
responses. FLT3 ligand (FLT3-L) is essential for DC development from hematopoietic progenitors. In a phase
I clinical trial, we demonstrated that immunotherapy with subcutaneous injection of FLT3-L is safe and well
tolerated in cancer patients recovering from autologous hematopoietic cell transplantation (HCT). FLT3-L
administration significantly increased the frequency and absolute number of blood DC precursors without
affecting other mature cell lineages during the 6-week course of FLT3-L therapy. After 14 days of FLT3-L
administration, the number of blood CD11c DCs, plasmacytoid DCs (PDCs), and CD14 monocytes
increased by 5.3-, 2.9-, 3.8-fold, respectively, and was maintained at increased levels throughout FLT3-L
therapy. FLT3-L–increased blood DCs in HCT patients were immature and had modest enhancing effects on
in vitro T-cell proliferation to antigens and natural killer (NK) cell function. The addition of type B CpG
oligodeoxynucleotides (ODNs) to peripheral blood mononuclear cells obtained from HCT patients receiving
FLT3-L therapy induced rapid maturation of both CD11c DCs and PDCs and enhanced T-cell proliferative
responses. In addition, CpG ODN induced potent activation of NK cells from FLT3-L–treated patients with
increased surface CD69 expression and augmented cytotoxicity. CpGODN–induced activation of NK cells was
primarily via an indirect mechanism through PDCs. These findings suggest that FLT3-L mobilization of DC
precursors followed by a specific DC stimulus such as CpG ODN may provide a novel strategy to manipulate
antitumor immunity in patients after HCT.
© 2005 American Society for Blood and Marrow Transplantation
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Dendritic cells (DCs) are professional antigen-
resenting cells (APCs) and display an extraordinary
apacity to stimulate T cell–mediated immune re-
ponses [1]. Recent studies suggest that DCs not only
lay a critical role in regulating the types of T-cell
esponses, but also regulate natural killer (NK) cell
ctivity against tumors and microbes [2,3]. Two dis-
inct human blood DC subsets, CD11c immature p
B&MTCs and CD11c plasmacytoid DCs (PDCs)—with
ifferent morphologies, phenotypes, and functional
roperties—have been identiﬁed [4]. Blood CD11c
Cs are considered to be myeloid derived, whereas
DCs, also known as type 1 interferon-producing
ells, are considered to be lymphoid related [4].
hereas CD11c DCs play a critical role in phago-
ytosis of microbial or apoptotic tumor cells, PDCs
lay a major role in antiviral immunity by rapidly
roducing large amounts of type 1 interferon after
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2iral infection. CD11cDCs express a set of Toll-like
eceptors (TLRs; TLR2, TLR3, TLR5, and TLR8)
hat is different from that expressed by PDCs (TLR7
nd TLR9) [5]. CD11c DCs can be selectively acti-
ated by double-stranded RNA (polyinosinic-poly-
ytidylic acid) through TLR3, whereas PDCs respond
o CpG DNA through TLR9 recognition and signal-
ng [6]. Developing new strategies to expand these
istinct DC populations in vivo and modulate their
unction associated with the speciﬁc regulation of host
mmunity may provide novel immune-based therapies
or cancer or viral diseases in patients after hemato-
oietic cell transplantation (HCT).
FLT3 ligand (FLT3-L) is a hematopoietic growth
actor that has a profound effect on the expansion and
obilization of stem cells and progenitors [7], and it
lays an important role in both DC and NK cell
ifferentiation from hematopoietic progenitor cells
8-10]. The importance of FLT3-L in the hematopoi-
sis of DCs has been demonstrated by the paucity of
hese cells in the FLT3-L deletional mutant mice [11].
njection of FLT3-L in mice dramatically increases
he numbers of both myeloid and lymphoid DCs in
lood and lymphoid tissues [12-16]. In humans, stud-
es have shown that the administration of FLT3-L
ncreases the number of CD11c DCs, PDCs, and
D14 monocytes in healthy volunteers [17,18]. The
mportant role of FLT3-L in human DC development
s also demonstrated by our recent study that FLT3-L
nd thrombopoietin synergistically promote the in
itro generation of large numbers of CD11c DCs,
DCs, and CD14 monocytes from CD34 hemato-
oietic progenitor cells [19]. FLT3-L is also critical
or NK cell development from stem cells and the
cquisition of NK cell receptors [20,21]. In mice,
LT3-L treatment increases the number of functional
K cells, and this may be important in cancer immu-
otherapy [22]. Given the effects of FLT3-L on the in
ivo expansion of DC precursors and NK cells in
ice, administration of FLT3-L in post-HCT pa-
ients may allow preferential modulation of host anti-
umor immunity.
Whether the in vivo FLT3-L–expanded DCs
ave enhancing effects on the immune function of
utologous T cells and NK cells in cancer patients is
nknown. To determine whether FLT3-L could aug-
ent human DC and NK cell number and function in
he HCT setting, a phase I trial of FLT3-L adminis-
ration was performed in cancer patients after autol-
gous HCT. In addition, we examined whether the
ddition of CpG oligodeoxynucleotides (ODNs) to
eripheral blood mononuclear cells (PBMCs) from
CT patients receiving FLT3-L therapy could in-
uce DC maturation associated with augmented T-
ell and NK cell function. Bacterial CpG DNA is a
otent immune stimulant, and its stimulatory ability is
onferred by the unmethylated CpG dinucleotides m
4nd the ﬂanking sequences presented in the DNA
23]. These sequences are registered as “danger” sig-
als by the TLR family, which comprises an elegant
athogen-recognition system for host defense in in-
ate immunity [24]. The receptor for CpG DNA is
dentiﬁed as TLR9 [24,25]. Recent studies have dem-
nstrated that ODNs containing the signature CpG
inucleotides (CpG ODNs) can rapidly mature hu-
an PDCs isolated from human blood [6,26,27]. CpG
DNs are currently being tested as immunotherapeu-
ic agents to induce antitumor activity in clinical trials.
revious studies by our group [28,29] and others
30,31] demonstrated in murine tumor models that
nhanced DC maturation and function by CpG
DNs strongly induce both T cell–mediated and NK
ell–mediated antitumor cellular immune responses
nd antitumor therapeutic effects in vivo. In this re-
ort, we present data that FLT3-L administration
afely increases the frequency and number of blood
C precursors in cancer patients after autologous
CT. The addition of CpG ODNs to PBMCs ob-
ained from FLT3-L–treated patients results in the
ctivation of DCs and the augmentation of autologous
-cell and NK cell function.
ATERIALS AND METHODS
atient Selection and Clinical Trial Design
Adult patients were eligible for this clinical trial
fter autologous HCT for Hodgkin disease, non-
odgkin lymphoma, or advanced-stage breast cancer.
atients received peripheral blood grafts mobilized
ith granulocyte-macrophage colony-stimulating fac-
or (GM-CSF) for days 1 to 4 (250 g/m2) followed
y granulocyte colony-stimulating factor (5 g/kg) on
ays 4 to 8; apheresis collections started on day 8.
atients who required chemotherapy as a part of their
obilization regimen received GM-CSF until their
hite blood cell count was 500/L; they then re-
eived granulocyte colony-stimulating factor for 4
ays, followed by apheresis. Cell collections continued
o obtain a desired graft size of 5  106 CD34 cells
er kilogram (or a minimal dose of 2  106 CD34
ells per kilogram). Patients received GM-CSF (250
g/m2) starting on day 1 after stem cell reinfusion
ntil the absolute neutrophil count was2500/L for
days. Patients were eligible to receive FLT3-L be-
ween day 84 and 112 after transplantation. They were
equired to have a complete response or stable disease,
table blood counts no longer requiring transfusions
r other growth factors, and no active infections and
o be capable of study participation in an outpatient
etting. After obtaining written informed consent ap-
roved by the Institutional Review Board at the Uni-
ersity of Minnesota, patients were treated with hu-
an recombinant FLT3-L (Amgen, Thousand Oaks,
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Effects of FLT3-L and CpG ODN on Human Dendritic Cells
BA) at 20 g/kg by subcutaneous injections every
ther day for 6 weeks on an outpatient basis. FLT3-L
as provided as a sterile, lyophilized preparation of
.5 or 5.0 mg of protein, 40 mg of mannitol, 10 mg of
ucrose, and 25 mmol/L tromethamine per vial. All
atients were treated with 21 alternate daily doses of
LT3-L within 6 weeks except for 1 patient, who
eceived 20 doses because of patient error.
BMC Preparation, Isolation, and Analysis of
lood Cell Populations
Blood samples from each patient were drawn be-
ore FLT3-L treatment on day 0 and every 14 days
fter the ﬁrst day of FLT3-L treatment for up to 2
onths (days 14, 28, 42, and 56). PBMCs from the
amples collected before or after FLT3-L treatment
ere isolated by Ficoll-Paque density gradient centrif-
gation. The cell populations present in PBMCs at
ifferent time points of FLT3-L treatment were de-
ermined by staining PBMCs with a cocktail of ﬂuo-
escein isothiocyanate (FITC)–conjugated antibodies
gainst lineage markers (CD3, CD14, CD16, CD19,
D20, and CD56, hereafter referred as Lin) and/or
ITC-, phycoerythrin (PE)–, APC-, or CyC-labeled
ntibodies against HLA-DR, CD3, CD4, CD8,
D14, CD19, CD56, CD34, CD11c, and CD123.
he frequency and absolute counts of blood
inDR DCs, LinDRCD11cCD123 DCs,
inDRCD11cCD123 PDCs, T cells, B cells,
K cells, monocytes, and CD34 cells present in
BMCs were identiﬁed and analyzed by ﬂow cytom-
try.
ligodeoxynucleotides
Phosphorothioate-modiﬁed CpG ODNs and con-
rol non-CpG ODNs were obtained from Coley
harmaceutical Group, Inc. (Wellesley, MA): ODN
006, tcgtcgttttgtcgttttgtcgtt; and ODN 2243, ggG-
GAGCATGCTCgggggG (sequences are shown
=-3=; lowercase letters indicate phosphorothioate
inkage, and bold indicates CpG dinucleotides). No
ndotoxin could be detected in ODN preparations
0.03 endotoxin units per mililiter; limulus amebo-
yte lysate assay; BioWhittaker, Walkersville, MD).
pG ODN 2006 and non-CpG ODN 2243 were
esuspended in Tris-ethylenediaminetetraacetic acid
uffer (10 mM Tris HCL/1mM EDTA, pH 8), di-
uted in phosphate-buffered saline, and used at ﬁnal
oncentrations of 3 g/mL.
low Cytometry Analysis
FITC-, PE-, APC-, or CyC-conjugated mouse
nti-human monoclonal antibodies (mAbs) directed
gainst CD3, CD4, CD8, CD14, CD19, CD40,
D45, CD54, CD80, CD83, CD86, CD123 (inter-eukin [IL]–3R), HLA-ABC, and HLA-DR antigens, 1
B&MTs well as isotype control mAbs, were obtained from
D PharMingen (San Diego, CA). FITC-conjugated
nti-Lin, PE-labeled anti-CD56, and APC-labeled
nti-CD11c antibodies were obtained from Becton
ickinson Immunocytometry Systems (San Jose, CA).
ells were stained with FITC-, PE-, APC-, or CyC-
onjugated mAbs for 45 minutes on ice, washed twice
ith Hanks buffered salt solution containing 0.2%
etal bovine serum (FBS), and ﬁxed with 0.2% para-
ormaldehyde phosphate-buffered saline. Mean ﬂuo-
escence intensity and positive cell percentages were
etermined by ﬂow cytometric analysis.
n Vitro Activation of Blood DCs and NK Cells
For in vitro activation of blood DCs and NK cells,
BMCs or puriﬁed DC subsets were cultured in 24-
ell plates at 5  106 cells per 2 mL of medium per
ell with or without the addition of ODN 2006
3 g/mL), polyinosinic-polycytidylic acid (50 g/mL),
ecombinant human IL-2 (500 U/mL), or other acti-
ation conditions as indicated. Cells were cultured in
37°C, 5% CO2 humidiﬁed incubator. After 48
ours, cultured cells were harvested and assessed for
heir phenotypic changes, antigen-presentation func-
ion, or NK-mediated cytolytic activity against a hu-
an NK-sensitive tumor target. The maturation-asso-
iated cell-surface markers (CD40, CD80, and CD86)
n DCs before and after ODN 2006 stimulation were
nalyzed by gating on the LinDRCD11cCD123
Cs and LinDRCD11cCD123 PDCs. The acti-
ation of NK cells in PBMCs after ODN 2006 stimu-
ation was analyzed by examining CD69 expression on
he gated CD56 cell population by ﬂow cytometry.
-Cell Proliferation Assays
Puriﬁed T cells in 10% human AB serum complete
edium (CM) consisting of RPMI 1640 supplemented
ith penicillin 100 U/mL, streptomycin 100 g/mL,
nd glutamine 2 mmol/L (all from Mediatech, Hern-
on, VA) were added at 2  105 cells per well in
6-well plates as responder cells. For the mixed leu-
ocyte reaction (MLR) assay, irradiated PBMCs (5000
Gy) from HCT patients were added to puriﬁed allo-
eneic T cells at the indicated concentration as stim-
lator cells, with or without preincubation under var-
ous activation conditions, for 48 hours. For antigen-
resentation experiments, PBMCs from HCT
atients before and during FLT3-L therapy were in-
ubated with various doses of tetanus toxoid (TT)
roteins (0.1 to 10 g/mL; Accurate Chemical, West-
rbury, NY) in a 5-day proliferation assay. In experi-
ents with the addition of ODN 2006, irradiated
BMCs from HCT patients were incubated with pu-
iﬁed autologous T cells plus various doses of TT in a
-day proliferation assay. The plates were pulsed with
Ci of 3H-thymidine per well for 18 hours before
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2arvesting. All determinations were performed in trip-
icate, and 3H-thymidine incorporation (counts per
inute; cpm) was determined. A stimulation index was
alculated by dividing the mean cpm of the experi-
ental group with the combination of mean cpm from
cells alone and APCs alone.
ytotoxicity Assays
Human NK-sensitive leukemia cell line K562 was
sed as target cells. The cell line was maintained in
0% FBS RPMI 1640 medium. Fresh or cultured
BMCs from HCT patients were used as effector
ells. Target cells were incubated at 37°C with 250
Ci of chromium 51 (New England Nuclear, Boston,
A) in 1 mL of 20% FBS CM for 45 minutes. La-
eled targets were washed 3 times and resuspended in
0% FBS CM at 105 cells per milliliter. Effector cells
n 100 L were added to 96-well plates followed by
04 labeled target cells. Plates were incubated for 4
ours at 37°C, and supernatant was harvested from
ach well and counted in a gamma counter. Maximum
pm were determined by lysing the targets alone with
.3% Triton-X solution, whereas minimum cpm were
etermined by targets in media alone. All determina-
ions of cytotoxicity were performed in triplicate with
t least 3 effector-target ratios. The percentage of lysis
as calculated with the following formula:
lysis (experimental mean cpm
 spontaneous release mean cpm) ⁄
(maximum release mean cpm
 spontaneous release mean cpm) 100%
ata Analysis
Data from patients or experiments are expressed as
ean  SD. Statistical analysis of the results between
roups was performed with the Student t test. Values
able 1. Patient Characteristics for the Clinical Trial
Diagnosis Age (y) Sex
Time from
to HCT
HL (MALT) 52 F 3
HL (mantle cell) 61 M 1
HL (follicular/large cell) 60 F 11
HL (large cell) 54 F
reast cancer 49 F 2
HL (follicular cell) 57 F 2
HL (large cell) 22 F
odgkin disease 32 M 2
ALT indicates mucosal-associated lymphoid tissue; cy, cyclop
prednisone; CVP, cy, vincristine; prednisone; DHAP, dexametha
cisplatin; XRT, radiation therapy; ABVD, doxorubicin bleomy
lymphoma.f P  .05 were considered signiﬁcant. H
6ESULTS
mmunotherapy with Subcutaneous Infusions of
LT3-L Is Safe and Well Tolerated in Patients
fter Autologous HCT
The main clinical objective was to test the safety
nd clinical tolerance of FLT3-L in patients after
utologous HCT. Six patients with non-Hodgkin
ymphoma, 1 patient with Hodgkin lymphoma, and 1
atient with advanced-stage breast cancer completed
heir participation in this phase I study (Table 1).
atients received mobilized hematopoietic cells with a
edian of 5.5 106 CD34 cells per kilogram (range,
.5-27  106/kg), and all engrafted promptly. Neu-
rophil recovery (absolute neutrophil count 500/L
or 3 days) was at a median of 11 days (range, 9-14
ays), and platelet recovery (20 000 for 3 days) was
t 15 days (range, 10-29 days). Ninety-ﬁve days
range, 64-110 days) after transplantation, patients
eceived posttransplantation immunotherapy with hu-
an recombinant FLT3-L (20 g/kg) by subcutane-
us injection every other day for 6 weeks. FLT3-L
as well tolerated without side effects in all post-
CT patients. There were no constitutional symp-
oms. All planned doses were administered except for
n erroneously missed dose in 1 patient.
LT3-L Effectively Increases the Frequency and
bsolute Number of Blood DC Precursors in
atients after Autologous HCT without Affecting
ther Mature Cell Lineages
Blood samples from patients were studied in vitro
o assess the frequency, absolute cell count, and func-
ion of circulating DC populations before FLT3-L
reatment (designated as day 0) and every 2 weeks
fter FLT3-L for up to 2 months (days 14, 28, 42, and
6) after HCT. Blood DC subsets were deﬁned as
inDR and had differential expression of CD11c
r CD123. Both blood DC subsets recovered after
osis
Prior Therapies (mo)
CHOP (4), XRT, DHAP (2)
CHOP (7), CVP (1), ESHAP (2)
Chlorambucil/CVP, CHOP (8), DHAP (2)
CHOP (6), then mitoxantrone, cy, ARA-C, prednisone
CA (4), docetaxel (2)
CHOP/CVP (10), rituxamab, CHOP (8), XRT
CHOP (8), XRT
ABVD (6), chemotherapy at relapse not specified (3)
mide; ARA-C, cytarabine; CHOP, cy, doxorubicin, vincristine,
isplatin, ARA- C; ESHAP, etoposide, methylprednisolone, ARA-C,
blastine, dacarbazine; CA, cy, doxorubicin; NHL, non-HodgkinDiagn
(mo)
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Effects of FLT3-L and CpG ODN on Human Dendritic Cells
Brequency of LinDR DCs, CD11c DCs, and
DCs in the PBMCs of HCT patients was 1.6%
1.63%  0.55%), 0.88% (0.088%  0.38%), and
.36% (0.38%  0.33), respectively, within 2 to 3
onths after HCT, similar to that in healthy donors
Figure 1). The absolute counts of leukocytes, neutro-
hils, lymphocytes, and platelets, as well as T cells, B
ells, NK cells, monocytes, and CD34 cells, present
n the PBMCs of HCT patients before FLT3-L treat-
ent (day 0) were in a normal range (Figures 2 and 3).
After 14 days of FLT3-L treatment, the frequen-
ies of circulating LinDR DCs, CD11c DCs,
DCs, and CD14 monocytes were increased to
.3% (7.32%  1.22%), 5.8% (5.8%  0.23%), 1.2%
1.24%  0.4%), and 39.2% (39.2%  18.7%) in the
BMCs of HCT patients, respectively (Figure 1C and
ata not shown). The absolute numbers of circulating
inDR DCs, CD11c DCs, PDCs, and CD14
onocytes were increased 7.6-, 5.3-, 2.9-, and 3.8-
old, respectively—higher than before FLT3-L treat-
ent. It is important to note that kinetic analysis
howed that prolonged injections of FLT3-L did not
urther increase the frequency and absolute number of
lood DC subsets and CD14 monocytes but main-
ained them at increased levels during the 6-week
ourse of FLT3-L treatment (Figure 2). Of note,
LT3-L infusion increased both blood CD11c DCs
nd PDCs; however, it preferentially increased
D11c DCs and altered the blood CD11c DC/
DC ratio from a 1.5 to 2.5 range to a ratio of 4.5 to
.0 within 14 days. After FLT3-L injections were
ompleted on day 42, the absolute number of blood
D11c DCs, PDCs, and CD14 monocytes de-
Normal DonorsA
1.09 ± 0.60
0.36 ± 0.09
0.69 ± 0.45
1.63 ± 0.55
2
1
0
HCT Patien
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DCs
PDCCD11c
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DCs
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Lin-DR+
DCs
igure 1. FLT3-L administration effectively increases the frequenc
solated from the peripheral blood of healthy donors (A) and from po
B) and at day 14 after FLT3-L therapy (C) were stained with FIT
nti-CD11c, and PE-conjugated anti-CD123 antibodies. The frequ
inDRCD11cCD123 PDCs in PBMC was determined by ﬂow
re expressed as mean  SD. Each symbol represents a single do
ercentages of DC subsets in blood samples from patients before F
signiﬁcant increase was obtained in the percentage of DC subset
.05) compared with that before FLT3-L therapy.lined to the normal range within 2 weeks. There was c
B&MTo signiﬁcant change in total leukocytes, neutrophils,
ymphocytes, or platelets in blood samples from the
CT patients before, during, or after the course of
LT3-L treatment (Figure 3). There was no signiﬁ-
ant difference in CD34 cells or T-cell, B-cell, or
K cell counts between blood samples from HCT
atients before, during, and after FLT3-L therapy.
hese results demonstrated that the administration of
LT3-L safely increases the frequency and absolute
ounts of blood DC precursors of patients after autol-
gous HCT without affecting other mature cell lin-
ages.
LT3-L–Expanded Blood DCs Are Immature and,
ithout Activation, Have Modest Enhancing
ffects on T-Cell and NK Cell Function
FLT3-L administration to cancer patients was
ased on the hypothesis that an increased presence of
irculating DCs might have profound effects on en-
ancing host antitumor immunity. It is interesting to
ote that phenotypic analysis of FLT3-L–increased
lood DCs showed negligible levels of CD40 and
D80 on both CD11c DCs and PDCs, indicating
hat they were immature. Despite the increase in
lood DCs after FLT3-L treatment, PBMCs from
LT3-L–treated HCT patients had a small and sta-
istically insigniﬁcant enhancement effect on the allo-
timulatory capability to induce T-cell proliferation as
ssessed in MLR (1.14- to 2.21-fold increase com-
ared with PBMCs before FLT3-L therapy; P  .05;
igure 4A). The capacity of PBMCs from HCT pa-
ients before and during FLT3-L therapy to enhance
he presentation of a recall antigen to autologous T
0.38
0.38 ± 0.33
C
Pre FLT3-L
On FLT3-L
8
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2
0
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HCT Patients
PDCc
+ Lin-DR+
DCs
PDCsCD11c
+
DCs
10 7.32 ± 1.22
5.8 ± 0.23
1.24 ± 0.4
ood DC subsets in cancer patients after autologous HCT. PBMCs
logous HCT patients enrolled in this study before FLT3-L therapy
ugated anti-Lin, CyC-conjugated anti–HLA-DR, APC-conjugated
circulating LinDR DCs, LinDRCD11cCD123 DCs, and
etric analysis. The percentages of DC subsets in the blood samples
patient tested. No signiﬁcant difference was found between the
therapy (n 	 8) compared with healthy donors (n 	 8; P  .05).
od samples from the patients at day 14 of FLT3-L treatment (*P0.88 ±
ts
CD11
DCs
y of bl
st–auto
C-conj
ency of
cytom
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2CT patients receiving FLT3-L therapy induced
roliferative responses of autologous T cells in a TT
ose–dependent manner, although the stimulation in-
ex was only slightly higher (1.36- to 2.58-fold) than
hat induced by TT-pulsed PBMCs from HCT pa-
ients before FLT3-L therapy, and a signiﬁcant dif-
erence was detected exclusively at high antigen doses
Figure 4B). NK cells in the PBMCs of HCT patients
eceiving FLT3-L therapy expressed negligible levels
f CD69 and exhibited low levels of cytolytic activities
igure 2. Prolonged FLT3-L administration maintained the incr
hroughout the 42-day therapy course. PBMCs isolated from blood
, 14, 28, 42, and 56) were stained with ﬂuorescent anti-Lin, HLA
ubsets and monocytes was determined by ﬂow cytometric analys
ercentages of LinDR DCs, LinCD11cCD123 DCs, Lin
epresentative HCT patient at different time points of FLT3-L tre
inDR DCs, CD11c DCs, PDCs and CD14 monocytes from
omparing the absolute counts of DCs at a speciﬁc time point of Fgainst K562. Killing of K562 targets by NK cells in h
8BMCs did not change signiﬁcantly on FLT3-L
reatment (Figure 4C). These ﬁndings demonstrated
hat FLT3-L–increased blood DCs are immature and,
ithout activation, have modest effects on enhancing
utologous T-cell and NK cell function.
LT3-L–Increased Blood DCs Can Be Matured by
pG ODN to Enhance Their Antigen Presentation
nd T Cell–Stimulatory Function
The ﬁnding that FLT3-L–increased blood DCs
umber of blood DC subsets and CD14 monocytes in patients
s of HCT patients before, during, and after FLT3-L therapy (days
D11c, CD123, or CD14 antibodies. The frequency of blood DC
he data show the ﬂow cytometric gates and kinetic changes of
clowCD123 PDCs, and CD14 monocytes in PBMC from 1
. B, The data show the kinetic changes of absolute counts of blood
T patients tested and are expressed as the mean  SD. *P  .05,
therapy with day 0.eased n
sample
-DR, C
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Buggests that these immature DCs require further
ctivation to enhance host immune function. Using
he blood samples obtained from HCT patients
eceiving FLT3-L therapy, we tested whether the
ddition of CpG ODN could activate FLT3-L–
ncreased DCs to enhance their antigen presenta-
ion and T cell–stimulatory function. Upon stimu-
ation with ODN 2006, blood CD11c DCs and
DCs both matured and increased surface expres-
ion of CD40, CD80, and CD86 within 48 hours
Figure 5A). As a control, the addition of the non-
pG ODN 2243 showed minimum effects on the
aturation of either DC subset. The allostimula-
ory capabilities of ODN 2006–stimulated PBMCs
rom HCT patients receiving FLT3-L therapy were
nhanced 4.3- to 6.7-fold compared with that with-
ut CpG ODN (P  .001; Figure 5B). In the pres-
nce of CpG ODN 2006, TT-pulsed PBMCs from
CT patients receiving FLT3-L induced signiﬁ-
antly higher proliferative responses of autologous
cells to TT; the stimulation index was 2.8- to
.4-fold higher than that without CpG ODN (P 
05; Figure 5C). These results demonstrate that
igure 3. FLT3-L therapy does not affect the absolute counts of
lood samples from each patient were drawn before FLT3-L treat
or up to 2 months (days 14, 28, 42, and 56). The absolute counts of
n blood samples of each patient were obtained and evaluated. The c
fter staining of PBMCs with multicolored ﬂuorescent antibodies
inetic changes of each cell population from all HCT patients tested
etween the absolute counts of these mature cell lineages at the
LT3-L therapy (day 0; P  .05).pG ODN can effectively mature FLT3-L–in- t
B&MTreased blood DCs to enhance their antigen presen-
ation and T cell–stimulatory function.
pG ODN 2006 Effectively Activates NK Cells in
BMCs from FLT3-L–Treated HCT Patients with
nhanced Cytolytic Activity
Our studies have shown that CpG ODNs can
ffectively activate human NK cells in PBMCs via
n indirect mechanism through blood PDCs [3].
K cells from HCT patients receiving FLT3-L
xpressed negligible CD69 levels. The addition of
DN 2006, but not ODN 2243, upregulated CD69
xpression on NK cells in PBMC (Figure 6A). Upon
ctivation with ODN 2006, NK cell activity in PB-
Cs obtained from FLT3-L–treated patients was
igniﬁcantly increased as assessed by cytotoxicity
gainst K562 cells (Figure 6B). In most HCT pa-
ients (5/7) tested, higher NK-mediated cytotoxicity
as induced in ODN 2006–stimulated PBMCs
rom HCT patients receiving FLT3-L than before
LT3-L therapy (Figure 6C). Depletion of PDCs
n PBMC from HCT patients receiving FLT3-L
efore ODN 2006 stimulation signiﬁcantly reduced
ature cell lineages in the peripheral blood of post-HCT patients.
t day 0 and every 14 days after the ﬁrst day of FLT3-L treatment
al white blood cells (WBC), neutrophils, lymphocytes, and platelets
ulations present in PBMC were further analyzed by ﬂow cytometry
against CD3, CD19, CD34, and CD56. The data shown are the
e expressed as the mean  SD. No signiﬁcant difference was found
ime points during FLT3-L therapy compared with those beforeother m
ment a
the tot
ell pop
speciﬁc
and ar
tested the CpG ODN, but not IL-2–induced augmenta-
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3ion of NK cell cytolytic activity (Figure 6D). This
esult is consistent with our ﬁndings with blood
amples from healthy donors that CpG ODN acti-
ates human NK cells predominately via an indirect
echanism through PDCs [32]. The results dem-
nstrate that CpG ODN can be used to effectively
nduce the activation and cytolytic function of NK
ells in blood samples from FLT3-L–treated HCT
atients.
ISCUSSION
Despite current advances in HCT, relapse contin-
es to be the main cause of treatment failure in pa-
ients treated with autologous transplantation. We are
nterested in developing safe and effective immuno-
herapy after HCT. FLT3-L administration has not
een previously tested in humans after HCT. In this
tudy, autologous HCT patients were enrolled to re-
eive FLT3-L treatment after successful engraftment.
hese HCT patients were evaluated for the clinical
afety of FLT3-L treatment and for the enhancing
ffects of FLT3-L on their immune function. We
how that immunotherapy with subcutaneous
LT3-L infusion is well tolerated in cancer patients
fter autologous HCT, without toxicity. We demon-
trate that FLT3-L therapy results in early recovery
nd a marked increase of CD11c DCs, PDCs, and
D14 monocytes in the peripheral blood of HCT
atients without affecting other mature cell lineages.
he prolonged injection of FLT3-L from days 14 to
2 did not further increase the frequency and absolute
umber of circulating DC precursors but effectively
aintained DCs at increased levels during the course
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igure 4. FLT3-L–increased blood DCs are immature and, without
, Graded numbers of irradiated PBMCs from HCT patients bef
uriﬁed allogeneic CD3 T cells in a 5-day MLR assay. B, Grade
LT3-L treatment were pulsed with various doses of TT (0.1-10 g
ssay. C, PBMCs from HCT patients before and during FLT3-L t
006 for 48 hours. NK cell–mediated cytolytic activity against K562
n each panel are aggregate results from 7 different HCT patientsf FLT3-L treatment. After FLT3-L injections were C
0iscontinued, the absolute number of blood DC pre-
ursors declined to the normal range within 2 weeks.
LT3-L administration greatly increased the frequen-
ies and absolute counts of blood DC subsets and
D14 monocytes in HCT patients, similar to pre-
ious reports by others of FLT3-L effects in healthy
olunteers [17,18]. Monitoring the immune recovery
f DC populations in HCT patients from the time of
ransplantation to engraftment may help to deﬁne the
est time point for FLT3-L treatment, because DC
ecovery might occur during a particular time period
fter HCT, and this may inﬂuence the outcome of
LT3-L administration on DCs. It is interesting to
ote that FLT3-L increased phenotypic immature
Cs in the peripheral blood of HCT patients; it had
nly modest effects on presenting either recall anti-
ens or alloantigens to induce T-cell responses and
ailed to augment the function of NK cells against
562 tumor targets. These ﬁndings suggest that
LT3-L–increased blood DCs require further matu-
ation to enhance host immune function.
CpG ODNs can effectively enhance DC maturation
nd strongly induce both T cell–mediated and NK cell–
ediated antitumor cellular immune responses and an-
itumor therapeutic effects in mice. Our studies have
hown that CpG ODNs are potent stimulators of NK
ell–mediated antitumor responses to protect naive mice
gainst a lethal acute myeloid leukemia challenge and
rotect syngeneic and allogeneic bone marrow trans-
lant recipients against acute myeloid leukemia chal-
enge at both early and late time points after transplan-
ation [28]. CpG ODNs are stable, chemically well
eﬁned, inexpensive agents with clinical-grade formulas
vailable for studies [23]. At least 3 distinct classes of
C.
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Bave recently been identiﬁed [33,34]. We chose to test
pG-B ODN (2006) in this study because CpG-B
DN (2006) is a potent stimulator for human DC mat-
ration and is now available in clinical grade (known as
DN 7909). Our results demonstrated that blood im-
ature DCs from FLT3-L–treated patients can be ef-
ectively activated by ODN 2006 with enhanced T cell–
timulatory function and augmented NK cell–mediated
ytotoxicity against K562 tumor targets. The require-
ent for CpGODN tomature FLT3-L–increased DCs
o enhance autologous T-cell and NK cell function sup-
orts the notion that this combination may lead to novel
trategies to manipulate immune responses against re-
idual tumor that may be present after autologous HCT.
igure 5. CpG ODN effectively induces the maturation of FLT3
ell–stimulatory function. A, PBMCs from HCT patients receiving
gainst blood CD11c DCs or PDCs. Cell-surface expression of CD
r PBMCs cultured for 48 hours in medium containing either OD
nalysis. The data shown are representative results from 1 of 5 rep
f irradiated PBMCs from patients receiving FLT3-L treatment we
006 in a 5-day MLR assay. C, Graded numbers of irradiated PBM
oses of TT (0.1-10 g/mL) and incubated with autologous CD3 T
hown in panels B and C are aggregate results from 5 different HC
006 group versus the no-CpG group.Our studies with blood samples obtained from f
B&MTealthy donors showed that although human NK cells
ack TLR9 expression (a TLR required for CpG recog-
ition), incubation of CpG ODN with PBMCs effec-
ively induced the activation of NK cells and augmented
K cytolytic activity. When PDCs were depleted from
BMC, the previously observed CpG ODN effect on
K cells was completely abrogated at various doses of
pG ODN tested. The addition of PDC to puriﬁed
DC-depleted NK cells effectively restored the CpG
DN effect on NK cells in a PDC dose–dependent
anner [32]. Comparable results were obtained in this
tudy with blood samples obtained from HCT patients
eceiving FLT3-L treatment. CpGODN effectively en-
anced NK cell cytotoxicity function in blood samples
reased blood DCs and enhances their antigen-presentation and T
-L therapy (day 14 or 28) were stained with ﬂuorescent antibodies
80, and CD86 on gated CD11c DCs and PDCs in fresh PBMCs
or ODN 2243 was compared and determined by ﬂow cytometric
le experiments from different HCT patients. B, Graded numbers
bated with puriﬁed allogeneic CD3 T cells with or without ODN
m patients receiving FLT3-L treatment were pulsed with various
with or without ODN 2006 in a 5-day proliferation assay. The data
nts expressed as mean  SD. *P  .05, comparing the CpG ODN-L–inc
FLT3
40, CD
N 2006
roducib
re incu
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cells
T patieromHCTpatients receiving FLT3-L.However, deple-
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3ion of blood PDCs increased by FLT3-L therapy com-
letely inhibited the CpG ODN effect on enhancing
K cell cytotoxicity activity. Similarly, human blood
D11c DCs also lack TLR9 expression [5]. In CpG
DN–stimulated PBMCs, blood CD11c DCs are ac-
ivatedmainly via an indirect mechanism through PDCs.
uman PDCs play a major role in antiviral immunity by
apidly producing large amounts of type 1 interferon
fter viral infection or bacterial DNA activation. The
ype 1 interferons produced by PDCs have striking in-
uences on the type of immune responses generated in
ivo. The critical role of PDCs in human antiviral im-
unity is suggested by the observation that the loss of
DCs correlates with disease progression to acquired
igure 6. CpG ODN effectively activates NK cells in PBMCs fro
DC-dependent manner. A, NK cells in PBMCs from HCT patient
ither ODN 2006 or ODN 2243 for 48 hours were stained with FI
y ﬂow cytometric analysis. Data are representative results from 1 of
CT patients receiving FLT3-L treatment were cultured in med
ctivity against K562 tumor targets was assessed in a standard 4-h
xpressed as mean  SD. C, PBMCs from patients before and dur
ssessed for NK cell–mediated lysis of K562 tumor targets in a 4-ho
, PBMCs from patients receiving FLT3-L treatment were deplete
orting before culturing with ODN 2006 or IL-2 for 48 hours. Cells
ytotoxicity assay. Data are representative of 3 HCT patients.mmunodeﬁciency syndrome in human immunodeﬁ- C
2iency virus–infected subjects [35]. In allogeneic bone
arrow transplantation, increasing evidence indicates
hat PDCs may play an important role in immune re-
ponses after HCT to facilitate engraftment and prevent
raft-versus-host disease [36-38]. Developing new strat-
gies to expand DC populations in vivo and modulate
heir function associated with the speciﬁc regulation of
he immunity in the host may provide novel immune-
ased therapies for cancer or viral diseases in posttrans-
lantation patients.
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